Receptor – Talk Bio

Jazz and Zymeworks’ Ziihera Achieves Practice-Changing Results in Phase 3 Trial for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

1 week ago talkbio0Tagged erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, Zanidatamab, Ziihera, Zymeworks

Ziihera; zanidatamab; Jazz Pharmaceuticals; Zymeworks; HER2; gastroesophageal adenocarcinoma; HERIZON-GEA-01; stomach cancer

Spotlight On: Five key oncology stories to watch in 2026

1 week ago talkbio0Tagged 2026, Antibody-Drug Conjugates, cancer research trends, CAR-T, Cell Therapy, Liquid Biopsy, Lymphocytes, Tumor-Infiltrating, mRNA cancer, Neoplasms, oncology decisions, precision oncology, Radiopharmaceuticals, T-Cell Receptor, United States Food and Drug Administration, Vaccines

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology

Lunit SCOPE AI Achieves High Concordance in HER2 Assessment for Biliary Tract Cancer

2 weeks ago talkbio0Tagged Agreement, Biliary Tract Cancer, erbB-2 Receptor, Lunit SCOPE, Medical pathologist, Pathology

Lunit SCOPE; HER2; biliary tract cancer; AI pathology; concordance; pathologists

Aviceda’s AVD-104 misses Phase 2b primary endpoint vs Izervay but still headed to Phase 3

1 month ago talkbio0Tagged avacincaptad, AVD-104, Clinical trial failure, Clinical Trials, Dry AMD, Genus Aviceda, Geographic Atrophy, IZERVAY, pegol, Phase 3 prospects, Sialic Acid Binding Immunoglobulin-like Lectins

Aviceda; AVD-104; geographic atrophy; dry AMD; Phase 2b; SIGLEC trial; Izervay; avacincaptad pegol; clinical trial failure; Phase 3 prospects

Tyra Biosciences Strengthens Leadership with Appointment of Bhavesh Ashar as COO and Heather Faulds as CRO

2 months ago talkbio0Tagged Bhavesh Ashar, biology (field), Chief Operating Officer, Chief Regulatory Officer, Drug Development, Fibroblast Growth Factor Receptors, Heather Faulds, Neoplasms, Precision Medicine, regulatory strategy, Tyra Biosciences

Tyra Biosciences; Bhavesh Ashar; Heather Faulds; Chief Operating Officer; Chief Regulatory Officer; oncology; precision medicine; FGFR biology; drug development; regulatory strategy

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at CTAD Conference

2 months ago talkbio0Tagged access program, Alzheimer 's disease, Clinical Trials, Cognition Therapeutics, CTAD, Lewy bodies, Neurodegenerative Disorders, Phase 3 clinical trial, Presenile dementia, sigma-2 receptor, Zervimesine

Cognition Therapeutics; Zervimesine; CT1812; Phase 3 clinical trial; Alzheimer’s disease; Clinical Trials on Alzheimer’s Disease (CTAD); neurodegenerative diseases; sigma-2 receptor; dementia with Lewy bodies; expanded access program

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

2 months ago talkbio0Tagged Biological Factors, buyback, erbB-2 Receptor, Jazz, Malignant neoplasm of stomach, milestone payments, Regulatory Filing, Royalty-Driven Model, Strategy, Ziihera, Zymeworks

Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing

Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed

2 months ago talkbio0Tagged Anemia, Sickle Cell, Biosimilars, Commissioner 's National Priority Voucher, Drug Approval, drug price, eli lilly, erbB-2 Receptor, Malignant neoplasm of lung, Obesity, Priority Review, public health medicine (field), Tuberculosis, Drug-Resistant, United States Food and Drug Administration, voucher program

FDA; Commissioner’s National Priority Voucher; priority review; drug approval; voucher program; Eli Lilly; Novo Nordisk; her2 lung cancer; obesity drugs; drug-resistant tuberculosis; sickle cell disease; biosimilars; public health; drug pricing; regulatory controversy

Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study

2 months ago talkbio0Tagged Antibodies, Bispecific, erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, orphan drug designation, Overall Survival, Pharmacotherapy, Phase 2 trial, Phase 3, practice-changing, Progression-Free Survival, Zanidatamab, Zymeworks

Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation

UbiVac Showcases First ‘Dark Matter’ Cancer Immunotherapy Clinical Data at SITC 2025 Annual Meeting

2 months ago talkbio0Tagged Allogeneic Autophagosome-enriched Vaccine DPV-001, alternatives, anti-PD-1, Clinical Trials, Combined Modality Therapy, Dark color, dark matter, Genome, immunopeptidome, Immunotherapy for cancer, Malignant Head and Neck Neoplasm, Neoantigen, SITC, T-Cell Receptor, UbiVac

UbiVac; DPV-001; cancer immunotherapy; dark matter; dark genome; alternatives neoantigens; T cell receptor (TCR); head and neck cancer; SITC 2025; clinical trial; combination therapy; anti-PD-1; immunopeptidome